Methods for inhibiting STAT3 signaling in immune cells

Details Methods for inhibiting STAT3 signaling in immune cells Methods for inhibiting STAT3 signaling in immune cells

2011-05-31

2011-05-31

Yu, Misook (Department: 1642)

Drug, bio-affecting and body treating compositions

Conjugate or complex of monoclonal or polyclonal antibody,...

C424S130100

Reexamination Certificate

active

07951374

ABSTRACT:
Methods of enhancing antitumor activity of an immune cell comprising contacting the immune cell with a Stat3 inhibitor are described. Also described are methods of killing a tumor cell or inhibiting tumor growth in a subject comprising contacting an immune cell of the subject with a Stat3 inhibitor.

REFERENCES:
patent: 5766947 (1998-06-01), Rittershaus et al.
patent: 5849790 (1998-12-01), Palmer et al.
patent: 6019966 (2000-02-01), Coleman et al.
patent: 6100090 (2000-08-01), Monia et al.
patent: 6265160 (2001-07-01), Leonard
patent: 2004/0038303 (2004-02-01), Unger
patent: 2004/0138189 (2004-07-01), Sebti et al.
patent: 2004/0175369 (2004-09-01), Yu et al.
patent: 2005/0074502 (2005-04-01), Turkson et al.
patent: 2005/0080131 (2005-04-01), Kay et al.
patent: 2005/0288365 (2005-12-01), Kay et al.
patent: 2006/0210536 (2006-09-01), Horvath et al.
patent: 2007/0031871 (2007-02-01), Jove
patent: 2007/0213288 (2007-09-01), Haura
patent: 02/20032 (2002-03-01), None
patent: 02/078617 (2002-10-01), None
patent: 2004/073650 (2004-09-01), None
patent: 2004/080394 (2004-09-01), None
patent: 2005/023824 (2005-03-01), None
patent: 2006/065894 (2006-06-01), None
Tannock et al, Experimental Chemotherapy in the Basic Science of Oncology, 1992, eds Tannock and Hill.
Cheung et al, Immunity, 2003, 19:425-436.
Mapara et al, J Clin Oncol, Mar. 2004 22:1136-1151.
Gura, Science, 1997, 278:1041-1042.
Almand, B. et al., “Clinical significance of defective dendritic cell differentiation in cancer,” Clin. Cancer Res. (2000) 6:1755-1766.
Alonzi, T. et al., “Induced somatic inactivation of Stat3 in mice triggers the development of a fulminant form of enterocolitis,” Cytokine (2004) 26:45-56.
Bartoli, M. et al., “VEGF differentially activates Stat3 in microvascular endothelial cells,” FASEB J. (2003) 17:1562-1564.
Benjamin, L.E. et al., “Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal,” J. Clin. Invest. (1999) 103:159-165.
Blaskovich, M.A. et al., “Discovery of JSI-124 (Cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice,” Cancer Res. (2003) 63:1270-1279.
Bowman, T. et al., “Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis,” PNAS (2001) 98:7319-7324.
Bromberg, J. et al., “The role of STATs in transcriptional control and their impact on cellular function,” Oncogene (2000) 19:2468-2473.
Brown, R.D. et al., “Dendritic cells from patients with myeloma are numercially normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD4OLT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10,” Blood (2001) 98(10):2992-2998.
Caamano, J. et al., “The NK-κB family member RelB is required for innate and adaptive immunity to toxoplasma gondii,” J. Immun. (1999) 163:4453-4461.
Catlett-Falcone, R. et al., “Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells,” Immunity (1999) 10:105-115.
Cheng, F. et al., “A critical role for Stat3 signaling in immune tolerance,” Immunity (2003) 19:425-436.
Costa-Pereira, A.P. et al., “Mutational switch of an IL-6 response to an interferon-γ-like response,” PNAS (2002) 99(12):8043-8047.
Dankbar, B. et al., “Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma,” Blood (2000) 95:2630-2636.
Darnell, J.E., Jr., “Transcription factors as targets for cancer therapy,” Nat. Rev. Cancer (2002) 2:740-749.
Deo, D. et al., “Phosphorylation of Stat-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor,JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism,” J. Biol. Chem. (2002) 277:21237-21245.
Dhodapkar, M.V. et al., “Antigen-bearing immature dendritic cells induce peptide-specific CD8+ regulatory T cells in vivo in humans,” Blood (2002) 100(1):174-177.
Donnelly, R.P. et al., “The interleukin-10 signal transduction pathway and regulation of gene expression in mononuclear phagocytes,” J. Interf. Cytok. Res. (1999) 19:563-573.
Dranoff, G. “Cytokines in cancer pathogenesis and cancer therapy,” Nature Reviews (2004) 4:11-22.
Dunn, G.P. et al., “Cancer immunoediting: from innunosurveillance to tumor escape,” Nature (2002) 3(11):991-998.
Ferlazzo, G. et al., “NK cell compartments and their activation by dendritic cells,” J. Immu. (2004) 1333-1339.
Ferrara, N., “VEGF and the quest for tumour angiogenesis factors,” Nat. Rev. Cancer (2002) 2:795-803.
Forsythe, J.A. et al., “Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1,” Mol. Cell Biol. (1996) 16:4604-4613.
Furumoto, K. et al., “Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses,” Int. J. Cancer (2000) 87:665-672.
Geldhof, A.B. et al., “Antagonistic effect of NK cells on alternatively activated monocytes: a contribution of NK cells to CTL generation,” Blood (2002) 100(12):4049-4058.
Gerber, H.P. et al., “Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells,” J. Biol. Chem. (1998) 273:13313-13316.
Golumbek, P.T. et al., “Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4,” Science (1991) 254:713-716.
Grandis, J.R. et al., “Constitutive activation of stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo,” PNAS (2000) 97(8):4227-4232.
Hawiger, D. et al., “Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo,” J. Exp. Med. (2001) 194(6):769-779.
Ho, W.Y. et al., “Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction,” Cancer Cell (2003) 3:431-437.
Huss, W.J. et al., “Selectively impairs angiogenesis to induce prostate cancer-specific apoptosis,” Mol. Cancer Ther. (2003) 2:611-616.
Inoue, M. et al., “VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis,” Cancer Cell (2002) 1:193-202.
Kanakaraj, P. et al., “Defective interleukin (IL)-18-mediated natural killer and T helper cell type 1 responses in IL-1 receptor-associated kinase (IRAK)-deficient mice,” J. Exp. Med. (1999) 189(7):1129-1138.
Kiertscher, S.M. et al., “Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells,” J. Immun. (2000) 164:1269-1276.
Klement, G. et al., “Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity,” J. Clin. Invest. (2000) 105:R15-24.
Klement, G. et al., “Differences in therapeutic indexes of combination metronomic chemoterapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts,” Clin. Cancer Res. (2002) 8:221-232.
Kobayashi, M. et al., “Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice,” J. Clin. Invest. (2003) 111(9):1297-1308.
Korpelainen, E.I. et al., “Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response,” Oncogene (1999) 18:1-8.
Kuhn, R. et al., “Inducible gene targeting in mice,” Scienc

Affiliated with

Also associated with

Rating

Methods for inhibiting STAT3 signaling in immune cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for inhibiting STAT3 signaling in immune cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for inhibiting STAT3 signaling in immune cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2699123